---
title: "Entyvio (vedolizumab) in ulcerative colitis: Access and coverage questions"
description: "Access and coverage questions on Entyvio (vedolizumab) in ulcerative colitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Cost and coverage, Access support, Prior authorization, and Patient support. Questions: What is the price (WAC) of Entyvio? Is there an Entyvio copay assistance program? Does the Entyvio copay program work with copay maximizer or accumulator plans? Can Medicare patients use Entyvio copay assistance or patient assistance? 7 further questions follow. 11 questions quoted from 6 sources."
canonical: "https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/access-and-coverage"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab) in ulcerative colitis: Access and coverage questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)

Access and coverage questions that apply to every indication of Entyvio are on [Entyvio (vedolizumab), all indications: Access and coverage](https://www.evicenter.com/medical-information/entyvio/access-and-coverage).

## Cost and coverage

<a id="entyvio-price"></a>

### What is the price (WAC) of Entyvio?

> “November 9, 2026 - **Wolters Kluwer is the source of this information.”

Source: [ENTYVIO: disclosure form, page 1, captured 2026-11-13](https://assets-dam.takeda.com/image/upload/LOC/en-us/home/corporate_responsibility/ethics_and_compliance/connecticut/Entyvio.pdf#page=1)

> “The list prices listed below are Wholesale Acquisition Costs (WAC). Information about WAC of 
> the drug(s) listed below is being provided to Connecticut prescribers and pharmacists pursuant 
> to Connecticut law. 
>
> • 
> The prices listed here reflect the list prices for the dosages and quantities described.  List prices 
> do not necessarily reflect price per dosage for any particular patient, the price per course of 
> treatment for any particular patient, or the cost effectiveness of the product.”

Source: [ENTYVIO: disclosure form, page 1, captured 2026-11-13](https://assets-dam.takeda.com/image/upload/LOC/en-us/home/corporate_responsibility/ethics_and_compliance/connecticut/Entyvio.pdf#page=1)

> “NDC Code 
> Takeda Products 
> WAC** 
> Package 
> Size 
> 64764-0300-20 
> Entyvio Intravenous Solution Reconstituted 300 MG 
> $10,108.70 1 vial 
> 64764-0108-21 
> Entyvio Subcutaneous Solution Pen-injector 108 MG/0.68ML 
> $3,639.14 
> 1 pen”

Source: [ENTYVIO: disclosure form, page 1, captured 2026-11-13](https://assets-dam.takeda.com/image/upload/LOC/en-us/home/corporate_responsibility/ethics_and_compliance/connecticut/Entyvio.pdf#page=1)

Note: Wholesale acquisition costs from the Connecticut WAC disclosure form dated November 9, 2026, which the Entyvio HCP site links in its page footer. Each price is for the package size listed beside it. The disclosure lists no price for the prefilled syringe (NDC 64764-107-11).

<a id="entyvio-copay-program"></a>

### Is there an Entyvio copay assistance program?

> “ENTYVIO Co-Pay Assistance Program can help eligible patients with commercial insurance pay as little as $0 per dose of ENTYVIO up to a total benefit of $20,000 per year.<sup>†</sup>”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=ENTYVIO%20Co%2DPay%20Assistance%20Program%20can,total%20benefit%20of%20%2420%2C000%20per)

> “<sup>†</sup>Terms and conditions apply. Must meet eligibility requirements.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=and%20conditions%20apply.%20Must%20meet%20eligibility%20requirements.)

> “The Co-Pay Program cannot be used if the patient is a beneficiary of, or any part of the prescription is covered by: 1) any federal, state, or government-funded healthcare program (Medicare, Medicare Advantage, Medicaid, TRICARE, etc.), including a state pharmaceutical assistance program (the Federal Employees Health Benefit (FEHB) Program is not a government-funded healthcare program for the purpose of this offer), 2) the Medicare Prescription Drug Program (Part D), or if the patient is currently in the coverage gap, or 3) insurance that is paying the entire cost of the prescription. Takeda reserves the right to change or end the Co-Pay Program at any time without notice, and other terms and conditions may apply.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=The%20Co%2DPay%20Program%20cannot%20be,terms%20and%20conditions%20may%20apply.)

> “The Co-Pay Program is for medication costs only and does not include costs to give you your treatment.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=The%20Co%2DPay%20Program%20is%20for,to%20give%20you%20your%20treatment.)

> “Patient may not seek reimbursement from any other plan or program (Flexible Spending Account [FSA], Health Savings Account [HSA], Health Reimbursement Account [HRA], etc.) for any out-of-pocket costs covered by the Co-Pay Program.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=Patient%20may%20not%20seek%20reimbursement,covered%20by%20the%20Co%2DPay%20Program.)

> “The Co-Pay Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider or health plan.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=The%20Co%2DPay%20Program%20only%20applies,insurance%20provider%20or%20health%20plan.)

Note: Program terms as captured from the Entyvio HCP patient support page on November 13, 2026; Takeda states it may change or end the program at any time. The maximum is $9,000 per calendar year when a health plan uses a copay maximizer program (see the copay maximizer question).

<a id="entyvio-copay-maximizer"></a>

### Does the Entyvio copay program work with copay maximizer or accumulator plans?

> “If you have enrolled in an accumulator adjustment, co-pay maximizer, or similar program that purports to help manage costs or later learn that your insurance company or health plan has implemented such a program, you agree to inform EntyvioConnect at 1-844-368-9846. In an accumulator adjustment program, payments made by you that are subsidized by a manufacturer co-pay assistance program do not count toward your deductibles and other out-of-pocket cost-sharing obligations. In a co-pay maximizer program, the amount of your out-of-pocket cost obligation is increased to match support offered by a manufacturer co-pay assistance program. It may be possible that you are unaware whether you are subject to these programs when you enroll in the Co-Pay Program. Takeda will monitor program utilization data and reserves the right to discontinue assistance under the Co-Pay Program at any time if Takeda determines that you are subject to a co-pay maximizer, accumulator, or similar program.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=If%20you%20have%20enrolled%20in,maximizer%2C%20accumulator%2C%20or%20similar%20program.)

> “Subject to all terms and conditions, the Maximum Annual Benefit under the Co-Pay Program is $20,000 per calendar year. However, except where prohibited by law, if your insurance company or health plan implements a co-pay maximizer program or similar program, you will have a reduced Maximum Annual Benefit of $9,000 per calendar year. If your insurance company or health plan removes ENTYVIO from such program, subject to all terms and conditions, you will be eligible for co-pay assistance up to the Maximum Annual Benefit for patients who are not subject to maximizer adjustment or similar programs.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=you%20your%20treatment.-,Subject%20to%20all%20terms%20and%20conditions%2C%20the%20Maximum%20Annual%20Benefit,maximizer%20adjustment%20or%20similar%20programs.)

> “This offer is not transferable and is limited to one offer per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, co-pay maximizer, alternative funding program, co-pay accumulator, or other offer, including those from third parties and companies that help insurers or health plans manage costs.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=This%20offer%20is%20not%20transferable,or%20health%20plans%20manage%20costs.)

Note: Program terms as captured from the Entyvio HCP patient support page on November 13, 2026. The program is for eligible commercially insured patients only; government-insured patients are excluded.

<a id="entyvio-medicare"></a>

### Can Medicare patients use Entyvio copay assistance or patient assistance?

> “The Co-Pay Program cannot be used if the patient is a beneficiary of, or any part of the prescription is covered by: 1) any federal, state, or government-funded healthcare program (Medicare, Medicare Advantage, Medicaid, TRICARE, etc.), including a state pharmaceutical assistance program (the Federal Employees Health Benefit (FEHB) Program is not a government-funded healthcare program for the purpose of this offer), 2) the Medicare Prescription Drug Program (Part D), or if the patient is currently in the coverage gap, or 3) insurance that is paying the entire cost of the prescription.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=The%20Co%2DPay%20Program%20cannot%20be,entire%20cost%20of%20the%20prescription.)

> “• In general, not have health coverage through private or government programs”

Source: [ENTYVIO: Enroll your patients, page 3, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/entyvioconnect-enrollment-form.pdf#page=3)

> “5. I understand that if I am eligible or enrolled in a Medicare plan, I will: 
> a) receive the requested medication from the Program for the remainder of the application calendar year for which my application was 
> approved, and I will not seek the requested medication from my Medicare plan for the remainder of the application calendar year;
> b) not seek true out-of-pocket (TrOOP) credit for any medication received from the Program because I understand that medication received 
> from the Program will not count toward my TrOOP; and
> c) agree to notify my Medicare plan that I will receive my Takeda medication for free until the end of the year through the Program;”

Source: [ENTYVIO: Enroll your patients, page 3, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/entyvioconnect-enrollment-form.pdf#page=3)

Note: The second passage is an eligibility condition, and the third a patient declaration, of the ENTYVIO Patient Assistance Program application in the EntyvioConnect enrollment form, which applies to patients approved for that program (see the patient assistance question). Terms as captured November 13, 2026.

<a id="entyvio-insurance-coverage"></a>

### Is Entyvio covered by commercial insurance?

> “ENTYVIO has broad, unrestricted commercial coverage for your patients.<sup>‡</sup>”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=ENTYVIO%20has%20broad%2C%20unrestricted%20commercial%20coverage%20for%20your)

> “<sup>‡</sup>For IV, unrestricted refers to coverage that does not require biologic step-edits. For pen, covered commercial lives include unrestricted coverage and biologic step-edits. Data are derived from Managed Markets Insight & Technology as of December 2025.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=IV%2C%20unrestricted%20refers%20to%20coverage,Technology%20as%20of%20December%202025.)

Note: Manufacturer statement based on Managed Markets Insight & Technology data as of December 2025, as captured November 13, 2026. For the Entyvio Pen, the manufacturer's covered-lives figure includes plans that require biologic step edits. The page gives no share of covered lives and no figure for Medicare or Medicaid.

## Access support

<a id="entyvio-patient-assistance"></a>

### Is there an Entyvio patient assistance program?

> “ENTYVIO Patient Assistance Program (PAP) helps patients with no health insurance or those whose benefits are insufficient to cover the cost of ENTYVIO and there is an identified financial need.<sup>†</sup>”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=ENTYVIO%20Patient%20Assistance%20Program%20%28PAP%29,there%20is%20an%20identified%20financial)

> “The ENTYVIO Patient Assistance Program (“ENTYVIO PAP”) provides 
> assistance for people who have no insurance or who do not have enough insurance and need help getting their Takeda medications. All applications are 
> reviewed on a case-by-case basis in accordance with program criteria. If you are currently covered for an ENTYVIO formulation, you may not be eligible for 
> the Patient Assistance Program.”

Source: [ENTYVIO: Enroll your patients, page 3, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/entyvioconnect-enrollment-form.pdf#page=3)

> “TO BE ELIGIBLE, ENTYVIO IV AND/OR PEN PATIENTS MUST MEET ALL OF THESE CONDITIONS:
> • Be a resident of the United States
> • Meet income criteria
> • Not have access to alternative sources of coverage or funding
> • Not be enrolled in an alternate funding or similar program. If you later learn that your insurance company or health plan has implemented such
> a program, you agree to inform EntyvioConnect at 1-844-368-9846
> • In general, not have health coverage through private or government programs
> • Other terms and conditions apply
> Applicants who are not approved for enrollment in the program may have the opportunity to seek an exception to the general program criteria.  
> This program can be discontinued or changed at any time without notice at the discretion of Takeda Pharmaceuticals U.S.A., Inc.”

Source: [ENTYVIO: Enroll your patients, page 3, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/entyvioconnect-enrollment-form.pdf#page=3)

Note: Eligibility terms from the EntyvioConnect enrollment form linked from the patient support page, as captured November 13, 2026.

<a id="entyvio-start-program"></a>

### Can commercially insured patients get Entyvio free after a coverage denial (Start Program)?

> “Start Program can help your eligible commercial patients start on ENTYVIO fast during insurance delays for $0 up to 3 years.<sup>†</sup>”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=Start%20Program%20can%20help%20your,for%20%240%20up%20to%203)

> “The Start Program provides ENTYVIO at no cost to eligible new-to-therapy patients who are excluded from coverage, 
> received a denial of coverage, and/or received a prior authorization denial from their commercial payer. Patients eligible 
> for federal or state healthcare programs (Medicare, Medicaid, TRICARE, etc.) are ineligible. Patients who experience a 
> Plan Exclusion due to Alternate Funding Program (AFP) involvement are not eligible for the Start Program. Patients must 
> have a valid prescription for ENTYVIO.”

Source: [ENTYVIO: Terms & conditions apply., page 1, captured 2026-11-13](https://www.entyvio.com/Content/pdfs/enrollment-terms.pdf#page=1)

> “Patients must submit evidence of denied coverage, excluded from coverage, or prior authorization denial from 
> their commercial payer and other required documents. There is no purchase obligation by virtue of a patient’s 
> participation in the Start Program. Free product provided through the Start Program is only available through the Start 
> Program’s contracted non-commercial Specialty Pharmacy. No claim for reimbursement for product dispensed through 
> the Start Program may be submitted to any third-party payer. Benefits provided under the Start Program are not 
> transferable. The Start Program is a one-time offer per patient. Eligibility will be determined on a case-by-case basis. 
> Takeda reserves the right to change or end the Start Program at any time, and other terms and conditions may apply.”

Source: [ENTYVIO: Terms & conditions apply., page 2, captured 2026-11-13](https://www.entyvio.com/Content/pdfs/enrollment-terms.pdf#page=2)

Note: Terms from the EntyvioConnect Terms and Conditions document (US-VED-4379v1.0, dated 06/26), linked from the Entyvio HCP home page, as captured November 13, 2026. The patient support page describes the program as covering insurance delays; the Terms and Conditions require a coverage exclusion, coverage denial, or prior authorization denial.

<a id="entyvio-bridge-program"></a>

### Does Entyvio have a bridge program for gaps in insurance coverage?

> “Bridge Program helps your commercial patients stay on track at no cost during gaps in insurance coverage for up to 6 months.<sup>†</sup>”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=Bridge%20Program%20helps%20your%20commercial,coverage%20for%20up%20to%206)

> “The Bridge Program provides continuity of care when an eligible ENTYVIO patient experiences a loss of or gap in 
> commercial insurance coverage or authorization. The Bridge Program provides up to 6 months of product at no cost to 
> enrolled patients while they obtain commercial coverage for ENTYVIO. Patients must be currently receiving ENTYVIO 
> therapy and experiencing a gap in or loss of commercial coverage. The Bridge Program is not available to patients who are 
> eligible for federal or state healthcare programs (Medicare, Medicaid, TRICARE, etc.). Patients who experience a Plan 
> Exclusion due to Alternate Funding Program (AFP) involvement are not eligible for the Bridge Program. Patients who have 
> not yet received their first dose of ENTYVIO are not eligible. There is no purchase obligation by virtue of a patient’s 
> participation in the Bridge Program. Free product provided through the Bridge Program is only available through the Bridge 
> Program’s contracted non-commercial Specialty Pharmacy. No claim for reimbursement for product dispensed through 
> the Bridge Program may be submitted to any third-party payer. Benefits provided under the Bridge Program are not 
> transferable. Eligibility will be determined on a case-by-case basis. Takeda reserves the right to change or end the Bridge 
> Program at any time, and other terms and conditions may apply.”

Source: [ENTYVIO: Terms & conditions apply., page 2, captured 2026-11-13](https://www.entyvio.com/Content/pdfs/enrollment-terms.pdf#page=2)

Note: Terms from the EntyvioConnect Terms and Conditions document (US-VED-4379v1.0, dated 06/26), linked from the Entyvio HCP home page, as captured November 13, 2026.

<a id="entyvio-specialty-pharmacy"></a>

### Which specialty pharmacies carry the Entyvio Pen?

Applies to: Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

> “For adult patients with moderately to severely active ulcerative colitis (UC)  
> or Crohn’s disease (CD) who are eligible to begin transitioning from 
> intravenous (IV) to subcutaneous (SC) maintenance treatment, the  
> ENTYVIO Pen can be ordered from any accredited specialty pharmacy (SP).”

Source: [ENTYVIO: Specialty Pharmacy Information, page 1, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/specialty-pharmacy-information.pdf#page=1)

> “The following SPs are preferred partners*:”

Source: [ENTYVIO: Specialty Pharmacy Information, page 1, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/specialty-pharmacy-information.pdf#page=1)

> “*The list of approved pharmacies is subject to change.”

Source: [ENTYVIO: Specialty Pharmacy Information, page 1, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/specialty-pharmacy-information.pdf#page=1)

> “AcariaHealth
> 1-800-511-5144 (TTY 711)
> Accredo
> 1-866-759-1557
> Alivia
> 1-888-925-1989
> CVS Caremark
> 1-800-378-5697
> Option Care
> 1-844-624-4584
> Optum Rx
> 1-800-711-4555
> Walgreens Specialty Pharmacy
> 1-800-516-9180”

Source: [ENTYVIO: Specialty Pharmacy Information, page 1, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/specialty-pharmacy-information.pdf#page=1)

Note: From the Specialty Pharmacy Information sheet (US-VED-2383v6.0, dated 05/26) linked from the Entyvio Pen dosing page, as captured November 13, 2026.

## Prior authorization

<a id="entyvio-prior-authorization"></a>

### How does prior authorization work for Entyvio and the Entyvio Pen?

> “PA requirements vary by health plan. Contact the patient’s health plan 
> to understand the specific PA requirements and specified submission 
> protocol (typically phone, fax, or web submission).
> For the ENTYVIO Pen: PAs for self-administered subcutaneous (SC) injections 
> with the ENTYVIO Pen are typically processed under a patient’s pharmacy 
> benefit. If this is the case, submit the PA [2-4 weeks] before their next scheduled 
> infusion date.”

Source: [ENTYVIO: PA Checklist, page 1, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/prior-authorization-checklist.pdf#page=1)

> “Collect the following information prior to submitting the PA as these 
> items may be necessary to obtain a PA decision from a health plan: 
> o Patient name, insurance policy number, and date of birth
> o Ordering physician’s name, contact information, tax ID, and NPI #
> o Treatment facility name, contact information, and tax ID
> o Date of service
> o Patient diagnosis (ICD-10-CM code[s]) as well as relevant procedure 
> and HCPCS codes if applicable for services/products to be 
> performed/provided
> o Product NDC
> o Any additional information specified by the health plan”

Source: [ENTYVIO: PA Checklist, page 1, captured 2026-11-13](https://www.entyviohcp.com/content/dam/takeda/imported/entyvio/pdfs/prior-authorization-checklist.pdf#page=1)

Note: From the EntyvioConnect Prior Authorization Checklist linked from the patient support page.

## Patient support

<a id="entyvio-patient-support"></a>

### What patient support services does EntyvioConnect offer?

> “A dedicated team will help you and your patients navigate insurance and affordability programs, including options that may make ENTYVIO available at no cost.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=A%20dedicated%20team%20will%20help,ENTYVIO%20available%20at%20no%20cost.)

> “Nurse Educators
>
> One-on-one guidance to help your patients stay on track with ENTYVIO and achieve their personal goals. They cannot, however, provide medical advice.
>
> Injection Training Nurses
>
> Your patients can receive a self-injection kit along with the option for virtual or in-person training with the ENTYVIO Pen.
>
> Patient Mentor Program
>
> Help patients connect with someone who understands their experience and can offer personal support.”

Source: [ENTYVIO: ENTYVIO® (vedolizumab) Patient Support & EntyvioConnect, captured 2026-11-13](https://www.entyviohcp.com/patient-support#accordion-5171dbd5cd-item-ea416c425c:~:text=Nurse%20Educators,and%20can%20offer%20personal%20support.)

## Related pages
- [Medical information: Entyvio (vedolizumab): Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)
- [Indication](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/guidelines)
